ClinicalTrials.gg
RecruitingNCT07270172MICRONUpdated Feb 2, 2026

The MICRON Study - A Steno 1 Substudy

An observational study in Type 1 Diabetes Mellitus, sponsored by University of Aarhus. Recruiting at 5 sites in Denmark. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by University of Aarhus · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University of Aarhus.

Started
2025
with 2 others
Observational
3 of 24
1 open now
Registered
22nd of 24
by date

Among the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 22nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, or all of them as a file.
02

Study summary

The goal of this observational study is to compare cardiac and renal oxygen consumption among subjects with type 1 diabetes treated with either multifactorial intervention or according to the current standard care. Participants are recruited from a main study /the Steno1 study) responsible for the intervention.

The main questions it aims to answer are if a multifactorial intervention in subjects with type 1 diabetes targeting cardiovascular and renal risk factors, will reduce cardiac and renal oxygen demand.

Participants will undergo the following examinations at 0-month, 6-month, and 24-month after enrolling in the main study:

  • Measurement of cardiac and real oxygen consumption ([11C]acetate PET/CT-scan)
  • Measurement of kidney function ([99mTc]DTPA GFR measurement)
  • Measurement of markers of heart and kidney disease in blood and urine samples.
Read the detailed description

In the MICRON study we will recruit participants from the ongoing CTIS approved Steno 1 study which is a prospective, cluster-randomized multicentre trial of 2000 persons with T1D. The Steno 1 study evaluates cardiovascular and renal effects of a multifactorial intervention vs. standard clinical care in subjects with type 1 diabetes (T1D) and established diabetic kidney disease (DKD), cardiovascular disease (CVD), heart failure, obesity or a >10% 5-year CVD risk using the Steno Risk Engine. The multifactorial intervention includes ambitious blood pressure and lipid targets as well as individualised pharmacological intervention with semglutide, sotagliflozin, and/or finerenone.

For the MICRON study we will recruit 20 persons from the ongoing Steno 1 study receiving multifactorial intervention as well as 20 persons from the Steno 1 study receiving standard care. No additional intervention is used for the MICRON study.

In the MICRON study each participant will undergo both [¹¹C]acetate PET/CT and [⁹⁹mTc]DTPAGFR measurements at baseline (inclusion) and again after 6 and 24 months of treatment (multifactorial intervention vs. standard care). At each of the three visits, blood and urine samples will be collected, along with anthropometric measurements.

The primary outcome variables, myocardial and renal oxygen consumption, will be assessed using [¹¹C]acetate PET/CT using a long axial field-of-view (LAFOV) PET scanner. Given that renal oxygen consumption is influenced by glomerular filtration rate (GFR), we will use [⁹⁹mTc]DTPA to accurately measure and account for variations in GFR when assessing renal oxygen consumption.

Three additional work packages WP2, WP3 and WP4 are to be conducted in collaboration with Steno Diabetes Centre Copenhagen, Monash University, Melbourne, Australia and the Department of Biomedicine, Aarhus University, Aarhus, Denmark investigating: WP2 Fibrosis, WP3 Oxidative stress and inflammation and WP4 Urinary extracellular vesicle proteomics.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Diabetic Kidney Disease
  • Diabetes-Related Complications
  • Renal oxygenation
  • Cardiac oxygenation
  • Renal inflammation
  • Renal fibrosis
  • Cardiovascular disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population for the Steno1 Study is persons with Type 1 Diabetes at the Steno Diabetes Centre and at partner clinics in Region Midt, Denmark. The MICRON study will recruit from these participants.

Eligibility criteria

Steno 1 inclusion criteria:

  • Male or female persons ≥40 years old with T1D (diagnosis before age 30 with insulin from onset or if diagnosis after 30 years of age insulin from onset and DKA or positive autoantibodies (in accordance with local guidelines), or confirmed, at the investigator's discretion by the available medical records) during >10 years.
  • Presence of chronic kidney disease (UACR >30 mg/g or \< 60 ml/min/1.73 m2) OR history of ischemic heart disease (previous myocardial infarction, stroke or angina) OR history of heart failure OR obesity grade 2 and 3 (>35 kg/m2) OR 5-year CVD risk >10% according to Steno Type 1 Risk Engine.
  • Fertile females must use highly efficient chemical, hormonal and mechanical during the whole study and at least 2 months after cessation of study drug. The following contraceptive methods are approved: IUD or hormonal contraception that inhibits ovulation, i.e. pills, implantations, transdermal patches, vaginal ring or depot injection. Alternatively, be in menopause (i.e. must not have had regular menstrual bleeding for at least one year), have undergone bilateral oophorectomy or have been surgically sterilized or hysterectomised at least 12 months prior to screening.
  • Ability to communicate with the investigator and understand .
  • Given written informed consent.

Steno 1 exclusion criteria:

  • Type 2 Diabetes, Maturity-onset diabetes of the young (MODY), secondary diabetes.
  • History of pancreatitis.
  • Body mass index \< 18.5 kg/m2
  • Females of who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods.
  • Known or suspected abuse of alcohol or recreational drugs.
  • Participant in another drug-intervention study.
  • Chronic Kidney Disease stage 5.

Additional exclusion criteria in the MICRON study:

  • Active malignant disease
  • Use of study drugs (SGLT inhibitors, GLP-1 RA, or finererone) at inclusion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Intervention group in the Steno 1 study

    Receiving the intensive treatment therapy in the Steno 1 Study. This consists of more ambitious blood pressure and lipid targets as well as individualised pharmacological intervention with GLP1 receptor agonist (semglutide), dual SGLT-1/2 inhibitor (sotagliflozin), and/or nonsteroidal mineralocorticoid receptor antagonist (finerenone).

  • Control group in the Steno 1 study.

    Receiving standart care in the Steno 1 Study.

06

What researchers measure

Primary outcomes

  1. Myocardial oxygen consumption

    Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time

    Time frame: At baseline (0 month), at 6 months and 24 months.

  2. Renal oxygen consumption

    Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time

    Time frame: At baseline (0 month), at 6 months and 24 months.

Secondary outcomes

  1. Myocardial external efficiency

    Measured by \[11C\]acetate PET/CT Unit: %

    Time frame: At baseline (0 month), at 6 months and 24 months.

  2. Myocardial perfusion

    Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time

    Time frame: At baseline (0 month), at 6 months and 24 month.

  3. Renal perfusion

    Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time

    Time frame: At baseline (0 month), at 6 months and 24 months.

  4. Amount of markers for oxidative stress and inflammation

    Exploratory analysis on pathways of oxidative stress and inflammation known to be involved in diabetic cardiorenal damage. Analysis on blood and urine samples.

    Time frame: Samples collected at baseline (0 month), at 6 months and 24 months.

  5. Amount of markers for renal fibrosis

    Exploratory measurements of renal extracellular matrix metabolism. Measurement of formation of collagen type III and VI (PRO-C3 and PRO-C6), endotrophin, and the collagen III degradation product C3M in blood and urine.

    Time frame: Samples collected at baseline (0 month), at 6 months and 24 months.

  6. Urinary extracellular vesicle

    Unbiased, large-scale quantitative proteomic profiling of urinary extracellular vesicles (uEVs). Functional interpretation uses Gene Ontology and pathway enrichment analyses, with emphasis on inflammation, mitochondrial oxygen consumption, and oxidative-stress-related pathways.

    Time frame: On urine samples collected at baseline (0 month), at 6 months and 24 months. Differential protein abundance is assessed longitudinally (baseline vs 6 and 24 months) and cross-sectionally between treatments at matched time points.

  7. Glomerular filtration rate

    Measured by \[99mTc\]DTPA Unit: ml/(min\*1,73 m\^2)

    Time frame: At baseline (0 month), at 6 months and 24 months.

  8. Urine albumin-creatinine ratio

    Measured by urine spots Unit: None

    Time frame: At baseline (0 month), at 6 months and 24 months. Moreover, results from in-clinic laboratory assessments will be collected during the study period if available.

Other outcomes

  1. Blood pressure

    Unit: mmHg

    Time frame: At baseline (0 month), at 6 months and 24 months.

  2. Plasma glucose

    Measured by POCT (Point-of-Care Testing)

    Time frame: Will be measured regularly (at least hourly) at the three study visits (baseline, 6 months, and 24 months) to monitor levels during fasting.

  3. Pro-brain natriuretic peptide

    Unit: Mass pr volumen

    Time frame: At baseline (0 month), at 6 months and 24 months.

  4. Troponin I

    Unit: Mass pr volumen

    Time frame: At baseline (0 month), at 6 months and 24 months.

  5. Blood lipids

    Total cholesterol, LDL, HDL and triglycerides. Unit: Mass pr volumen

    Time frame: At baseline (0 month), at 6 months and 24 months.

  6. Liver enzymes

    Alanine transaminase (ALAT) and aspartate transaminase (ASAT). Unit: Mass pr volumen.

    Time frame: At baseline (0 month), at 6 months and 24 months.

  7. Hemoglobin A1c

    Unit: mmol/mol

    Time frame: At baseline (0 month), at 6 months and 24 months.

  8. Thyroid-stimulating hormone (TSH)

    Unit: amount pr volumen.

    Time frame: At baseline (0 month), at 6 months and 24 months.

  9. Blood ketones

    Unit: amount per volumen

    Time frame: At baseline (0 month), at 6 months and 24 months.

  10. eGFR

    Unit: mL/min/1,73 m2

    Time frame: At baseline (0 month), at 6 months and 24 months.

  11. Electrolytes

    Sodium + Potassium Unit: mass pr

    Time frame: At baseline (0 month), at 6 months and 24 months.

  12. Trombocytes

    Unit: amount pr volumen.

    Time frame: At baseline (0 month), at 6 months and 24 months.

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Stougaard EB, Andersen MR, Bagger JI, Sondergaard E, Ostergaard JA, Curovic VR, Persson F, Almdal T, Mathiesen AS, Andries A, Bohl M, Norgaard LJ, Dejgaard TF, Dorfinger GH, Gustenhoff P, Gaede PH, Hamid YH, Johannesen HL, Juhl CB, Jorgensen ME, Kielgast U, Kofoed-Enevoldsen A, Lindhardt M, Mortensen LS, Thomsen HH, Stidsen J, Sorensen LP, Urhammer S, Rossing P; Steno 1 Study Group. The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study. Diabetes Obes Metab. 2025 Oct;27(10):5432-5443. doi: 10.1111/dom.16606. Epub 2025 Jul 29. PubMed 40726451 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 33 months is close to that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 8, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07270172
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Oct 27, 2025
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 2, 2026

Study contacts

Sofie H Wilken, MD, PhD student
Contact
shw@clin.au.dk
004523653656
Jakob A Østergaard, MD, PhD
Contact
jakooest@rm.dk
004520912226
Jakob A Østergaard, MD, PhD
principal investigator · Steno Diabetes Centre Aarhus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion